RT Journal Article
SR Electronic
T1 A pilot study of 18F-DCFBC PET/CT imaging for tumor detection in prostate cancer patients with biochemical relapse after definitive treatment
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1555
OP 1555
VO 57
IS supplement 2
A1 Lindenberg, Maria Liza
A1 Mena, Esther
A1 Turkbey, Ismail
A1 Adler, Stephen
A1 Ton, Anita
A1 McKinney, Yolanda
A1 Weaver, Juanita
A1 Eclarinal, Philip
A1 Kwarteng, Gideon
A1 Couvillon, Anna
A1 Citrin, Deborah
A1 Pinto, Peter
A1 Dahut, William
A1 Pomper, Martin
A1 Choyke, Peter
YR 2016
UL http://jnm.snmjournals.org/content/57/supplement_2/1555.abstract
AB 1555Objectives 18F DCFBC is a low molecular weight, urea based small molecule targeting an external binding domain of PSMA. Found in almost all prostate cancers, PSMA is a promising target for imaging and therapy. Patients with biochemical recurrence after definitive therapy for prostate cancer are frequently treated empirically with pelvic irradiation and accurate localization of disease could enable more targeted therapy with decreased morbidity related to treatment. We aimed to evaluate the utility of using 18F DCFBC, for tumor detection in patients with biochemical relapse of prostate cancer. Methods This is a prospective IRB-approved study including 34 prostate cancer patients (65 ± 6 yo, range 57 - 82 yo), Gleason score at diagnosis was 7 [range 6 to 9], with rising PSA after total prostatectomy (n = 30) or after salvage radiation therapy (n = 4). Median PSA= 2.0 ± 7.5 ng/ml [range 0.22 - 37.19]. All patients underwent 18F DCFBC PET/CT imaging [average dose: 279.1 MBq, ranged 222 - 296 MBq] at 1 h and 2 hours after intravenous injection. Histology (when available) was used to correlate PET findings. Results Of the total 34 patients analyzed, 18F DCFBC scans were positive in 9 (median PSA 3.33 ng/ml, range 1.31 - 37.19), indeterminate in 12 (median PSA 1.94 ng/ml, range .39 - 11.26) and negative in 13 patients (median PSA 1.39 ng/ml, range .22 - 5.66). Positive lesions were detected in nodes and soft tissues of the pelvis in 3 patients, and outside the pelvis in 6 patients. Histologic confirmation was provided in 7 patients. There was 1 true positive, 1 false positive, and 1 false negative finding. The indeterminate group had 3 negative biopsy results and 1 positive biopsy. Conclusions 18F DCFBC shows promise as an imaging tool for patients with biochemically recurrent prostate cancer after definitive treatment. Further analysis compared to multiparametric MRI and more histologic samples will be helpful for this group, especially in the clinically important range of low PSA values which may further influence clinical management.